MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
2026: Medtech Big 100: The world’s largest medical device companies
Glaukos Corporation (NYSE: GKOS)
Organization & Developments: Glaukos
Parents
Glaukos Corporation (NYSE: GKOS)
Children
*Creating a new class of micro-bypass therapies to achieve sustainable target intraocular pressures through the restoration of physiologic outflow
*Focused on treating glaucoma
*Glaukos devices are tiny titanium tubes which are implanted inside the eye via a minimally invasive procedure that increases flu
*The promise of the technology is that it could be a definitive solution for glaucoma and eliminate the need for most medications
2016: Glaukos: $15 Target Price If More Insurers Change Reimbursements - Glaukos (NYSE:GKOS)
2018: Glaucoma Surgery Space Heats Up with New Approval
2018: Glaukos wins FDA approval for treatment managing glaucoma patients’ IOP_seekingalpha.com
2019: Glaukos Continues its Evolution with Avedro Acquisition
2019: Glaukos Keeps Its Eye on the Prize at JP Morgan
2022: Glaukos (GKOS) Investor Presentation - Slideshow_ seekingalpha.com
2023: Glaukos wins FDA approval for drug-releasing eye implant to treat glaucoma
2024: Glaukos: Still Bullish, But Embedded Expectations Are Now High
2025: Glaukos Corporation: Delivering Consistent Growth
Jumps
*Key People: Glaukos
Finance & Acquisitions: Glaukos